AngioDynamics, Inc. (ANGO) Spending and interest coverage
- R&D / revenue · 12 months: Value 9.20%; Formula and calculation Research and development expense / revenue. Period ending 2026-05-31..
- Stock-based compensation / revenue · 12 months: Value 4.36%; Formula and calculation Share-based compensation / revenue. Period ending 2026-05-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 9.20% | Research and development expense / revenue. Period ending 2026-05-31. $29.45M ÷ $320.17M × 100 ≈ 9.20% |
| Stock-based compensation / revenue · 12 months | 4.36% | Share-based compensation / revenue. Period ending 2026-05-31. $13.96M ÷ $320.17M × 100 ≈ 4.36% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 29.45M USD | Research and Development Expense |
| Revenue | 320.17M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 13.96M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -39.93M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $29.45M | $320.17M | $13.96M | $-39.93M | (m) | 9.20% | 4.36% | (m) | (m) |
| 2026-02-28 | $27.86M | $313.73M | $11.69M | $-35.52M | (m) | 8.88% | 3.72% | (m) | (m) |
| 2025-11-30 | $27.69M | $307.31M | $11.40M | $-32.54M | (m) | 9.01% | 3.71% | (m) | (m) |
| 2025-08-31 | $26.35M | $300.72M | $11.04M | $-37.51M | (m) | 8.76% | 3.67% | (m) | (m) |
| 2025-05-31 | $26.22M | $292.50M | $9.77M | $-39.95M | (m) | 8.96% | 3.34% | (m) | (m) |
| 2025-02-28 | $26.36M | $283.32M | $10.03M | $-48.62M | (m) | 9.30% | 3.54% | (m) | (m) |
| 2024-11-30 | $27.63M | $286.50M | $10.24M | $-238.54M | (m) | 9.64% | 3.57% | (m) | (m) |
| 2024-08-31 | $29.86M | $292.73M | $9.59M | $-240.56M | (m) | 10.20% | 3.28% | (m) | (m) |
| 2024-05-31 | $31.51M | $303.91M | $10.53M | $-192.44M | $-1.61M | 10.37% | 3.46% | (m) | Reported |
| 2024-02-29 | $32.65M | $324.01M | $11.61M | $-198.82M | $-146.00K | 10.08% | 3.58% | (m) | Reported |
| 2023-11-30 | $31.31M | $329.54M | $10.80M | $-7.86M | $984.00K | 9.50% | 3.28% | -7.98× | Reported |
| 2023-08-31 | $29.49M | $335.89M | $12.28M | $-2.85M | $2.20M | 8.78% | 3.66% | -1.29× | Reported |
| 2023-05-31 | $29.88M | $338.75M | $11.16M | $-51.18M | $2.70M | 8.82% | 3.29% | -18.94× | Reported |
| 2023-02-28 | $29.89M | $334.68M | $11.08M | $-36.74M | $1.99M | 8.93% | 3.31% | -18.50× | Reported |
| 2022-11-30 | $30.32M | $327.93M | $11.63M | $-33.11M | $1.42M | 9.24% | 3.55% | -23.27× | Reported |
| 2022-08-31 | $31.68M | $320.79M | $11.29M | $-33.67M | $913.00K | 9.88% | 3.52% | -36.88× | Reported |
| 2022-05-31 | $30.74M | $316.22M | $10.69M | $-28.47M | $688.00K | 9.72% | 3.38% | -41.38× | Reported |
| 2022-02-28 | $31.98M | $306.06M | $10.02M | $-43.66M | $688.00K | 10.45% | 3.27% | -63.46× | Reported |
| 2021-11-30 | $33.26M | $303.27M | $9.81M | $-42.10M | $741.00K | 10.97% | 3.24% | -56.82× | Reported |
| 2021-08-31 | $34.77M | $297.76M | $9.19M | $-38.26M | $802.00K | 11.68% | 3.09% | -47.71× | Reported |
| 2021-05-31 | $36.39M | $291.01M | $8.63M | $-35.28M | $861.00K | 12.50% | 2.96% | -40.98× | Reported |
| 2021-02-28 | $34.52M | $272.50M | $7.99M | $-170.31M | $911.00K | 12.67% | 2.93% | -186.95× | Reported |
| 2020-11-30 | $34.35M | $271.10M | $7.62M | $-172.81M | $851.00K | 12.67% | 2.81% | -203.06× | Reported |
| 2020-08-31 | $32.40M | $268.33M | $7.47M | $-171.39M | $657.00K | 12.07% | 2.78% | -260.87× | Reported |
| 2020-05-31 | $29.68M | $264.16M | $7.59M | $-167.10M | $907.00K | 11.24% | 2.87% | -184.23× | Reported |
| 2020-02-29 | $29.34M | $277.01M | $8.13M | $-7.55M | $2.08M | 10.59% | 2.93% | -3.63× | Reported |
| 2019-11-30 | $27.86M | $272.75M | $8.73M | $-4.99M | $3.36M | 10.22% | 3.20% | -1.49× | Reported |
| 2019-08-31 | $27.18M | $272.73M | $9.08M | $-4.09M | $4.65M | 9.96% | 3.33% | -0.88× | Reported |
| 2019-05-31 | $28.26M | $270.63M | $9.25M | $-9.40M | $5.10M | 10.44% | 3.42% | -1.84× | Reported |
| 2019-02-28 | $28.69M | $351.50M | $9.21M | $11.53M | $4.53M | 8.16% | 2.62% | 2.55× | Reported |
| 2018-11-30 | $27.94M | $349.01M | $8.89M | $13.60M | $3.83M | 8.00% | 2.55% | 3.56× | Reported |
| 2018-08-31 | $26.68M | $344.21M | $8.27M | $10.74M | $3.26M | 7.75% | 2.40% | 3.30× | Reported |
| 2018-05-31 | $25.46M | $344.29M | $7.91M | $10.56M | $3.06M | 7.39% | 2.30% | 3.45× | Reported |
| 2018-02-28 | $25.70M | $342.88M | $6.93M | $-5.21M | $2.91M | 7.50% | 2.02% | -1.79× | Reported |
| 2017-11-30 | $25.20M | $344.63M | $6.56M | $-4.93M | $2.79M | 7.31% | 1.90% | -1.77× | Reported |
| 2017-08-31 | $25.00M | $346.96M | $6.30M | $9.54M | $2.84M | 7.21% | 1.81% | 3.35× | Reported |
| 2017-05-31 | $25.27M | $349.64M | $6.18M | $12.97M | $2.84M | 7.23% | 1.77% | 4.57× | Reported |
| 2017-02-28 | $25.51M | $356.15M | $3.82M | $22.58M | $2.96M | 7.16% | 1.07% | 7.63× | Reported |
| 2016-11-30 | $25.37M | $357.98M | $3.77M | $19.40M | $3.13M | 7.09% | 1.05% | 6.19× | Reported |
| 2016-08-31 | $25.63M | $358.24M | $3.30M | $4.38M | $3.32M | 7.16% | 0.92% | 1.32× | Reported |
| 2016-05-31 | $25.05M | $353.89M | $3.24M | $1.02M | $3.40M | 7.08% | 0.92% | 0.30× | Reported |
| 2016-02-29 | $25.48M | $351.22M | $6.11M | $6.41M | $3.35M | 7.25% | 1.74% | 1.91× | Reported |
| 2015-11-30 | $26.52M | $350.43M | $5.96M | $-6.42M | $3.40M | 7.57% | 1.70% | -1.89× | Reported |
| 2015-08-31 | $26.41M | $353.35M | $6.23M | $-3.17M | $3.20M | 7.48% | 1.76% | -0.99× | Reported |
| 2015-05-31 | $26.93M | $356.97M | $6.00M | $-994.00K | $3.20M | 7.54% | 1.68% | -0.31× | Reported |
| 2015-02-28 | $26.37M | $360.14M | $5.87M | $1.25M | $2.98M | 7.32% | 1.63% | 0.42× | Reported |
| 2014-11-30 | $26.56M | $361.69M | $5.98M | $17.91M | $3.04M | 7.34% | 1.65% | 5.89× | Reported |
| 2014-08-31 | $27.52M | $358.11M | $5.65M | $14.78M | $3.21M | 7.68% | 1.58% | 4.61× | Reported |
| 2014-05-31 | $27.51M | $354.45M | $5.41M | $13.45M | $3.66M | 7.76% | 1.53% | 3.68× | Reported |
| 2014-02-28 | $27.20M | $350.42M | $5.26M | $11.66M | $4.41M | 7.76% | 1.50% | 2.65× | Reported |
| 2013-11-30 | $25.94M | $343.80M | $4.66M | $4.15M | $4.76M | 7.55% | 1.35% | 0.87× | Reported |
| 2013-08-31 | $25.95M | $342.20M | $4.64M | $7.70M | $5.18M | 7.58% | 1.36% | 1.48× | Reported |
| 2013-05-31 | $26.32M | $342.03M | $4.61M | $7.09M | $5.27M | 7.70% | 1.35% | 1.35× | Reported |
| 2013-02-28 | $25.10M | $309.68M | $4.46M | $-984.00K | $4.17M | 8.11% | 1.44% | -0.24× | Reported |
| 2012-11-30 | $23.88M | $279.68M | $4.59M | $-3.80M | $3.00M | 8.54% | 1.64% | -1.27× | Reported |
| 2012-08-31 | $21.99M | $250.76M | $4.41M | $-5.00M | $1.72M | 8.77% | 1.76% | -2.90× | Reported |
| 2012-05-31 | $20.51M | $221.79M | $4.09M | $-2.96M | $508.00K | 9.25% | 1.84% | -5.83× | Reported |
| 2012-02-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-05-31 | $21.37M | $215.75M | $4.61M | $11.96M | $499.00K | 9.91% | 2.14% | 23.97× | Reported |
| 2011-02-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-05-31 | $19.27M | $216.03M | $4.88M | $20.87M | $672.00K | 8.92% | 2.26% | 31.06× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |